Comparison of outcomes between patients with de‐novo sinonasal squamous cell carcinoma vs malignant transformations from inverted papillomas

2020 ◽  
Vol 10 (6) ◽  
pp. 762-767
Author(s):  
Huatao Quan ◽  
Haiyan Zhang ◽  
Lifen Zou ◽  
Wei Yuan ◽  
Shengzi Wang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
De Novo ◽  
Malignant Transformations ◽  
Inverted Papillomas

scholarly journals The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung

2017 ◽  
Vol 38 (4) ◽  
pp. 2189-2196 ◽  
Author(s):  
Tomoyuki Igarashi ◽  
Koji Teramoto ◽  
Mitsuaki Ishida ◽  
Jun Hanaoka ◽  
Yataro Daigo
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
De Novo

scholarly journals Cisplatin-Resistance in Oral Squamous Cell Carcinoma: Regulation by Tumor Cell-Derived Extracellular Vesicles

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1166 ◽  
Author(s):  
Xin-Hui Khoo ◽  
Ian C. Paterson ◽  
Bey-Hing Goh ◽  
Wai-Leng Lee
Keyword(s):  
Drug Resistance ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Extracellular Vesicles ◽  
Squamous Cell ◽  
Metal Ion ◽  
De Novo ◽  
Protein Profile ◽  
Severe Problem

Drug resistance remains a severe problem in most chemotherapy regimes. Recently, it has been suggested that cancer cell-derived extracellular vesicles (EVs) could mediate drug resistance. In this study, the role of EVs in mediating the response of oral squamous cell carcinoma (OSCC) cells to cisplatin was investigated. We isolated and characterized EVs from OSCC cell lines showing differential sensitivities to cisplatin. Increased EV production was observed in both de novo (H314) and adaptive (H103/cisD2) resistant lines compared to sensitive H103 cells. The protein profiles of these EVs were then analyzed. Differences in the proteome of EVs secreted by H103 and H103/cisD2 indicated that adaptation to cisplatin treatment caused significant changes in the secreted nanovesicles. Intriguingly, both resistant H103/cisD2 and H314 cells shared a highly similar EV protein profile including downregulation of the metal ion transporter, ATP1B3, in the EVs implicating altered drug delivery. ICP-MS analysis revealed that less cisplatin accumulated in the resistant cells, but higher levels were detected in their EVs. Therefore, we inhibited EV secretion from the cells using a proton pump inhibitor and observed an increased drug sensitivity in cisplatin-resistant H314 cells. This finding suggests that control of EV secretion could be a potential strategy to enhance the efficacy of cancer treatment.

Sinonasal inverted papilloma involving the temporal bone via the eustachian tube: case report

2013 ◽  
Vol 127 (3) ◽  
pp. 318-320 ◽  
Author(s):  
Z W Liu ◽  
A Walden ◽  
C A Lee
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Temporal Bone ◽  
Eustachian Tube ◽  
Squamous Cell ◽  
Inverted Papilloma ◽  
Subsequent Transformation ◽  
Sinonasal Inverted Papilloma ◽  
Pubmed Search ◽  
Inverted Papillomas

AbstractObjective:This study reports a case of a sinonasal inverted papilloma with spread to the temporal bone via the eustachian tube and subsequent transformation to squamous cell carcinoma.Method:An 81-year-old woman presented with sinonasal inverted papilloma which subsequently spread to the ear. A literature review of inverted papilloma was carried out based on a Pubmed search of studies published between 1987 and 2011, using the key words ‘sinonasal inverted papilloma’, ‘temporal bone inverted papilloma’ and ‘squamous cell carcinoma’.Results and conclusion:Sinonasal and temporal bone inverted papillomas may sometimes be linked through direct spread via the eustachian tube. Inverted papillomas have the potential for malignant transformation; careful monitoring of both the nose and ear is therefore required for inverted papillomas found in the nasopharynx.

CAPTN: A nomogram for predicting survival and guiding therapy for patients with de novo metastatic head and neck squamous cell carcinoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 6041-6041 ◽  
Author(s):  
Jared R. Robbins ◽  
Michael Stadler ◽  
Monica Shukla ◽  
Selim Firat ◽  
Becky Massey ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
De Novo ◽  
Neck Squamous Cell Carcinoma

Primary Intracranial Squamous Cell Carcinoma Arising De Novo: A Case Report and Review of the Literature

2018 ◽  
Vol 120 ◽  
pp. 372-381 ◽  
Author(s):  
Xiaochao Liu ◽  
Zhongping Chen ◽  
Yutong Dong ◽  
Xin He ◽  
Xingchen Pan ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
De Novo ◽  
Review Of The Literature

scholarly journals Diagnosis of Therapy-related Acute Myeloid Leukemia with t(8;21)(q22;q22.1) after Treatment for Mantle Cell Lymphoma and Oral Squamous Cell Carcinoma

2019 ◽  
pp. 1-7
Author(s):  
Patrícia Colombo Corrêa ◽  
Íris Mattos Santos-Pirath ◽  
Chandra Chiappin Cardoso ◽  
Camila Mattiolo ◽  
Bruno Vieira Dias ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mantle Cell Lymphoma ◽  
Squamous Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Correct Diagnosis ◽  
Treatment Strategies ◽  
Mantle Cell

Aims: We report a rare case of therapy-related AML with t(8;21)(q22;q22.1) that occurred after treatment for mantle cell lymphoma (MCL) and oral squamous cell carcinoma (OSCC). Presentation of Case: A 52 years-old male patient was diagnosed with MCL in leukemic phase. The treatment consisted in R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, then patient experienced remission. Three months later, he presented a lump that was diagnosed as OSCC, which was surgically removed and treated with cisplatin and radiotherapy. Then, the patient’s hemogram presented 35.0% of blasts and, after morphologic, phenotypic and molecular analysis, it was classified as AML with t(8;21)(q22;q22.1). However, due to the previous historic of chemotherapy and radiotherapy, the final diagnosis was t-AML. Discussion: The correct diagnosis of therapy related malignancies is important due to its severity as they are very aggressive and, usually, considered incurable. t-AMLs with t(8;21)(q22;q22.1) is considered as favorable karyotype, still, it has a poorer outcome compared with its de novo counterpart. Conclusion: t-AML with t(8;21)(q22;q22.1) is rare and few cases are described in the literature. More reports are necessary to better elucidate the mechanisms involved in this disease to define better treatment strategies to prevent these events and to improve the poor outcomes.

scholarly journals How I treat anal squamous cell carcinoma

ESMO Open ◽  
2020 ◽  
Vol 4 (Suppl 2) ◽  
pp. e000711
Author(s):  
Giulia Martini ◽  
Gianluca Arrichiello ◽  
Carola Borrelli ◽  
Luca Poliero ◽  
Erika Martinelli
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
De Novo ◽  
Checkpoint Inhibitors ◽  
Early Stage ◽  
Single Agent ◽  
Hpv Infection ◽  
Anal Squamous Cell Carcinoma ◽  
Systemic Treatments

Squamous cell carcinoma of the anus (SCCA) is a rising health issue, strongly related to other relevant medical conditions such as (HIV) and human papillomavirus (HPV) infection. Correct assessment of patients with SCCA requires a multidisciplinary evaluation and adequate follow-up. Accurate local and systemic staging, as well as risk evaluation, are essential to optimal treatment planning. Early stage tumours can be definitively treated with a combination of chemotherapy and radiotherapy, while salvage surgery is usually reserved for patients who develop local recurrence. Distant recurrence and de novo metastatic disease are associated with poorer prognosis and require palliative systemic chemotherapy, with different single agent and combination options available. Finally, recent discoveries on the carcinogenesis of SCCA have allowed the development of innovative treatment options, the most promising being immune checkpoint inhibitors. The limited systemic treatments for SCCA and low incidence of the disease, together with insufficient data from clinical research could explain the poor outcomes of these patients, which should therefore be managed in high volume centres and enrolled in clinical trials whenever possible. This article summarises the main strategies for treating patients with SCCA.

Sign in / Sign up

Export Citation Format

Share Document